EverGlade Lands ModeX Therapeutics Up to $168 Million in BARDA Funding
EverGlade, a national consulting firm, has helped ModeX Therapeutics successfully secure up to $168 million in funding through a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) to develop novel multispecific antibodies against viral infectious disease threats. How Funding Will Be Used The $168 million in BARDA funding will advance research and clinical trials for multispecific antibodies, […]
EverGlade Lands ModeX Therapeutics Up to $168 Million in BARDA Funding Read More »